ClinicalTrials.gg

Program

Amphotericin B

Also written as “Amphotericin B Liposome for Injection (strength: 50 mg, Sichuan Huiyu Pharmaceutical Co., Ltd.)”, “Amphotericin B Liposome for Injection (trade name: Ambisome®, strength: 50 mg, MAH: Gilead Sciences)” and “Amphotericin B Liposome”.

Its studies are mostly in Meningitis, Cryptococcal · Invasive Fungal Infections · Leishmaniasis, Visceral · Aspergillosis · Candidiasis, led by 9 companies.

Furthest: phase 3, since Nov 2, 199914 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer60 open or runningphase 3since Nov 2, 1999Nov 2, 1999none ahead
Alkermes10 open or runningphase 1since Nov 2, 1999Nov 2, 1999none ahead
Aurobindo Pharma10 open or runningphase 1since Aug 6, 2018Aug 6, 2018none ahead
Bristol-Myers Squibb10 open or runningno phasesince Nov 2, 1999Nov 2, 1999none ahead
Johnson & Johnson10 open or runningphase 3since Nov 2, 1999Nov 2, 1999none ahead
Liposome10 open or runningno phasesince Nov 2, 1999Nov 2, 1999none ahead
Matinas BioPharma Nanotechnologies10 open or runningphase 2since Nov 16, 2015Nov 16, 2015none ahead
Merck10 open or runningphase 2since Feb 5, 2004Feb 5, 2004none ahead
Sichuan Huiyu Pharmaceutical10 open or runningno phasesince Apr 30, 2025Apr 30, 2025none ahead

Also a collaborator on its studies: axis-clinicals-limited.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 2, 1999First study: phase 1 study in Meningitis, CryptococcalNew to AlkermesAlkermes · NCT00002316 · United States
  2. Nov 2, 1999First studies: 4 no phase studies in Meningitis, CryptococcalNew to PfizerPfizer · NCT00002305, NCT00002075, NCT00002074 and 1 more
  3. Nov 2, 19992 phase 3 studiesPfizer · NCT00002277, NCT00001017
  4. Nov 2, 1999First study: phase 3 study in HIV InfectionsNew to Johnson & JohnsonJohnson & Johnson · NCT00002159 · 60 enrolled · United States
  5. Nov 2, 1999First study: no phase study in CandidiasisNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT00002041 · United States
  6. Nov 2, 1999First study: no phase study in Meningitis, CryptococcalNew to LiposomeLiposome · NCT00002019 · United States
  7. Feb 5, 2004Merck's first study: phase 2 study in AspergillosisNew to MerckMerck · NCT00076869 · 55 enrolled
  8. Nov 16, 2015Matinas BioPharma Nanotechnologies's first study: phase 2 study in Candidiasis, Chronic MucocutaneousNew to Matinas BioPharma NanotechnologiesMatinas BioPharma Nanotechnologies · NCT02629419 · 4 enrolled · United States
  9. Aug 6, 2018Aurobindo Pharma's first study: phase 1 study in Leishmaniasis, VisceralNew to Aurobindo PharmaAurobindo Pharma · NCT03636659 · 140 enrolled · Bangladesh, India
  10. Apr 30, 2025Sichuan Huiyu Pharmaceutical's first study: no phase study in Invasive Fungal InfectionsNew to Sichuan Huiyu PharmaceuticalSichuan Huiyu Pharmaceutical · NCT06977490 · 42 enrolled · China

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Ergosterol sequestering agent”ChEMBL 37, by rule

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06977490Invasive Fungal Infections · China–CompletedSichuan Huiyu PharmaceuticalOct 7, 202542
NCT03636659Leishmaniasis, Visceral · Bangladesh, India1CompletedAurobindo PharmaApr 5, 2019140
NCT02629419Candidiasis, Chronic Mucocutaneous · United States2CompletedMatinas BioPharma NanotechnologiesNov 9, 20214
NCT00076869Aspergillosis2CompletedMerckSep 200455
NCT00002316Meningitis, Cryptococcal · United States1CompletedAlkermes
NCT00002305Meningitis, Cryptococcal · United States, Canada–CompletedPfizer
NCT00002277Mycoses · United States3CompletedPfizer
NCT00002159HIV Infections · United States3CompletedJohnson & Johnson60
NCT00002075Meningitis, Cryptococcal · United States–CompletedPfizer
NCT00002074Meningitis, Cryptococcal · United States, Canada–CompletedPfizer
NCT00002068Meningitis, Cryptococcal · United States, Canada–CompletedPfizer
NCT00002041Candidiasis · United States–CompletedBristol-Myers Squibb
NCT00002019Meningitis, Cryptococcal · United States–CompletedLiposome
NCT00001017Meningitis, Cryptococcal · United States3CompletedPfizerJul 1991330

How it is read

Names in the registry

  • “Amphotericin B”, 11 entries
  • “Amphotericin B Liposome for Injection (strength: 50 mg, Sichuan Huiyu Pharmaceutical Co., Ltd.)”, 1 entry
  • “Amphotericin B Liposome for Injection (trade name: Ambisome®, strength: 50 mg, MAH: Gilead Sciences)”, 1 entry
  • “Amphotericin B Liposome”, 1 entry
  • “Comparator: amphotericin B”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.